Loading patent…
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsMichael A. Gimbrone, Jr., Myron I. Cybulsky, Tucker Collins
Estimating the term…
The invention relates to novel endothelial cell-leukocyte adhesion molecules designated ATHERO-ELAM. ATHERO-ELAM molecules are expressed on cultured endothelial cells stimulated with bacterial LPS and selectively mediate the binding of monocytes to the endothelial cells. Monoclonal antibodies specific for ATHERO-ELAM bind to vascular endothelial cells involved in early atherosclerotic lesions, but not to vascular endothelial cells from uninvolved arterial tissue. ATHERO-ELAM and antibodies directed to ATHERO-ELAM may be used in identifying early atherosclerotic lesions and in treating and preventing atherosclerosis.
A substantially purified protein comprising a mononuclear leukocyte-selective endothelial-leukocyte adhesion molecule expressed in atherosclerotic lesions having the amino acid sequence shown in Sequence ID 2, and comprising an AS-1 domain between domains 3 and 4 of said protein and wherein said protein is selected from the group consisting of:
A substantially purified protein comprising an AS-1 domain between immunoglobulin-like domains 3 and 4 of a mononuclear leukocyte-selective endothelial-leukocyte molecule expressed in atherosclerotic lesions, said protein lacking transmembrane and cytoplasmic domains, wherein said protein comprises the sequence between amino acids 1 and 774 in Sequence ID 2, and wherein said protein is selected from the group consisting of:
Dependencies are inferred from the claim text.